Q-omics provides the consensus-scored IFT140 profile across patient tissues and cancer cell-line models. IFT140 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IFT140 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, IFT140 protein abundance shows 22,958 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, THCA, and LUAD as cancer lineages where IFT140 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFT140 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFT140 survival associations across molecular data types. IFT140 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFT140 RNA expression–survival associations across cancer types. High IFT140 expression shows unfavorable associations in LGG, LUAD and CESC, but favorable associations in HNSC, BRCA and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IFT140 RNA expression.
This table summarizes IFT140 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFT140. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFT140 shows lower tumor expression in THCA, KICH and LUAD and higher tumor expression in COAD, KIRP and LIHC. The THCA box plot shows higher IFT140 RNA expression in normal versus tumor tissue (log2 FC = −1.451, t-test p < 0.001).
This table shows molecular features associated with IFT140 in patient tissues and cancer cell lines. In patient samples, IFT140 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IFT140 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
